AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
The Group will continue to make proactive investments of its management resources in the life science business
The new facility is scheduled to start operation in the first half of 2024
Subscribe To Our Newsletter & Stay Updated